Lenacapavir

Contraindicated

Lenacapavir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine toxicity Details Lenacapavir Encorafenib Braftovi Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details

Major

Lenacapavir Acetaminophen And Codeine Capital® & Codeine Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-mediated adverse reactions Details Lenacapavir Buprenorphine Belbuca Explained Increased or reduced buprenorphine exposure Details Lenacapavir Relugolix Orgovyx Explained Increased relugolix exposure Details Lenacapavir Simvastatin Flolipid Explained Increased simvastatin exposure Details Lenacapavir Abemaciclib Verzenio Explained Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Acalabrutinib Calquence Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Aliskiren Tekturna Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Lenacapavir Apixaban Eliquis Explained Increased apixaban exposure and increased risk of bleeding Details Lenacapavir Atogepant Qulipta Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Avapritinib Ayvakit Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Betrixaban Bevyxxa® Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Lenacapavir Afatinib Gilotrif Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Lenacapavir Avanafil Stendra Increased sensitive CYP3A substrate exposure Details Lenacapavir Bosutinib Bosulif Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Brexpiprazole Rexulti Increased brexpiprazole exposure Details Lenacapavir Budesonide Entocort Increased sensitive CYP3A substrate exposure and an increased risk of Cushing's syndrome and adrenal suppression Details Lenacapavir Budesonide Nasal Spray Rhinocort Increased sensitive CYP3A substrate exposure and an increased risk of Cushing's syndrome and adrenal suppression Details Lenacapavir Budesonide Oral Inhalation Pulmicort Increased sensitive CYP3A substrate exposure and an increased risk of Cushing's syndrome and adrenal suppression Details Lenacapavir Cobimetinib Cotellic Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Cyclosporine Injection Atopica Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Lenacapavir Cyclosporine Ophthalmic Cequa Increased sensitive P-gp/CYP3A substrate exposure and an increased risk of sensitive P-gp/CYP3A substrate-related adverse effects Details Lenacapavir Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Lenacapavir Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Lenacapavir Darolutamide Nubeqa Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Lenacapavir Dasatinib Phyrago Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Dexamethasone Injection Decadron Increased dexAMETHasone exposure, an increased risk of Cushing's syndrome and adrenal suppression, reduced lenacapavir exposure an... Details Lenacapavir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Increased dexAMETHasone exposure, an increased risk of Cushing's syndrome and adrenal suppression, reduced lenacapavir exposure an... Details Lenacapavir Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin-related adverse reactions Details Lenacapavir Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure Details Lenacapavir Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure Details Lenacapavir Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Lenacapavir Edoxaban Savaysa Increased edoxaban exposure and an increased risk of edoxaban-related adverse reactions Details Lenacapavir Elacestrant Orserdu Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Entrectinib Rozlytrek Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Lenacapavir Everolimus Afinitor Increased everolimus exposure Details